Adamis Pharmaceuticals reported $2.42M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Adamis Pharmaceuticals ADMP:US USD 2.42M 6.46M
Adma Biologics ADMA:US USD 34.91M 17.51M
Brainstorm Cell Therapeutics BCLI:US USD 4.14M 4.86M
Cara Therapeutics CARA:US USD 42.81M 3.91M
GlaxoSmithKline GSK:LN GBP 3.61B 2.86B
Glaxosmithkline GSK:US GBP 3.61B 2.86B